Eligibility requires a BMI of 30 or higher, or 27 with weight-related health issues, along with previous attempts at lifestyle changes
Daily intraperitoneal administration for 11 days reduced body weight gain, decreased white adipose tissue mass by approximately 35%, and reduced adipocyte size, while food intake between treated and control groups did not differ significantly
1.3.2 Vitamin D Vitamin D plays a neuroprotective role by regulating calcium homeostasis, modulating immune function, and attenuating amyloid beta (A) and tau induced neurotoxicity (Grimm et al., 2017)
Liraglutide, a once-daily human GLP-1 analogue, provides sustained improvements in glycaemic control and weight for two years as monotherapy compared with glimepiride in patients with type 2 diabetes
Most GLP-1 patches remain investigational and are not yet FDA-approved for clinical use